Navigation Links
InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
Date:11/6/2008

- Third quarter net loss narrows on higher revenue due to Roche milestone -

BRISBANE, Calif., Nov. 6 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced results from operations for the third quarter and nine months ended September 30, 2008. InterMune reported a net loss for the third quarter of 2008 of $12.5 million, or $0.32 per share, compared with a net loss of $23.1 million, or $0.66 per share, in the third quarter of 2007.

Dan Welch, Chairman, Chief Executive Officer and President of InterMune said, "Third quarter and recent events have highlighted our significant progress on pirfenidone and ITMN-191. On October 16, Shionogi's Japanese NDA for pirfenidone was approved, making pirfenidone the first drug approved for idiopathic pulmonary fibrosis (IPF) in any major market in the world. We reported exceptional patient retention in our Phase 3 CAPACITY program for pirfenidone in IPF and we set the expectation for announcement of top-line results from CAPACITY in January or February of 2009. With ITMN-191, we remain committed to announcing top-line results of our triple combination study of ITMN-191 with Pegasys(R) (pegylated interferon alfa-2a) and Copegus(R) (ribavirin) during this quarter."

Results for Third Quarter 2008

InterMune reported total revenue in the third quarter of 2008 of $23.3 million, compared with total revenue of $11.4 million in the third quarter of 2007. Total revenue in the third quarter of 2008 primarily consisted of revenue from the collaboration with Roche for the development of protease inhibitors, including ITMN-191 (R7227), which totaled $15.8 million in the third quarter of 2008, compared with $0.8 million in the same quarter of 2007. Third quarter 2008 collaborati
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. InterMune to Present at Citigroup Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014  AtheroNova Inc. (OTCBB: AHRO), a biotech ... compounds to safely regress atherosclerotic plaque and improve ... partner, CardioNova, has accomplished first dosing of subjects ... lead compound, AHRO-001.  This Phase 1b trial will ... safety trial completed in February 2014, in which ...
(Date:7/30/2014)... 30, 2014 NCERC at Southern ... present his findings on corn stover pretreatment methods ... week in Washington, D.C. , “Arun’s selection ... is a testament to the success of our ... “Thanks to the foresight and vision of SIUE ...
(Date:7/30/2014)... July 30, 2014 Vala Sciences ... U.S. Environmental Protection Agency (EPA). This new contract ... toxicity models, including tests designed to assess the ... the formation of connections between neurons (synapses), which ... and synapse formation by environmental pollutants likely contributes ...
(Date:7/30/2014)... July 30, 2014 Immunology ... leading Immunologists, Principle Investigators, scientists in the field, ... Malemud, Professor at Case Western Reserve University School ... keynote address on “The effects of recombinant ... of matrix metalloproteinase-9”. Arya Biragyn, a Senior investigator ...
Breaking Biology Technology:AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 2NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 3U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3Unveiling Breakthroughs in Clinical & Cellular Immunology 2Unveiling Breakthroughs in Clinical & Cellular Immunology 3
... ... ... Therapeutic Proteins Inc. (TPI) today announced the completion of the nation’s first independent, ... Administration (FDA) requirements. The Chicago facility is located at University Technology Park at ...
... ... and Existing Partnerships , ... April 21, 2010 -- HealthTalker , the leader in word of mouth (WOM) marketing ... Core Leadership Team as the Senior Director of Strategic Partnerships. , , , ...
... situations, a split second can make the difference between ... of new "smart sensors" that allow for faster response ... new research from NC State that will help ensure ... those faced in Afghanistan or elsewhere. "We,ve taken ...
Cached Biology Technology:Therapeutic Proteins Inc. Completes First Independent, Dedicated Biosimilars Manufacturing Facility in U.S. 2Therapeutic Proteins Inc. Completes First Independent, Dedicated Biosimilars Manufacturing Facility in U.S. 3Therapeutic Proteins Inc. Completes First Independent, Dedicated Biosimilars Manufacturing Facility in U.S. 4HealthTalker Adds Industry Expert Collie Turner to Its Executive Team 2
(Date:7/30/2014)... 2014 NexID Biometrics , a ... solutions for the biometric authentication industry, has recently ... online authentication with standards for strong authentication. According ... decision to join FIDO Alliance stems from NexID,s ... use. We believe the FIDO Alliance is a ...
(Date:7/30/2014)... CHAMPAIGN, Ill. Scientists are searching through a massive ... more than 50 years ago, and the effort is ... world they inhabited. , When the collection is fully ... will be the largest unbiased Dominican amber collection in ... most striking discovery thus far is that of a ...
(Date:7/30/2014)... of iodine-125 (125I) in cancer treatment has been ... ganglia are critical for neural transmission between the ... and colleagues from Institute of Radiation Medicine, Chinese ... could be implanted into rat dorsal root ganglia ... seeds with different radioactivity (0, 14.8, 29.6 MBq) ...
Breaking Biology News(10 mins):NexID Biometrics Joins the FIDO Alliance 2Decades-old amber collection offers new views of a lost world 2
... The National Science Foundation (NSF) today announced Science ... collaboration among scientists and educators around the globe ... common interests and goals, SAVI can better leverage ... society,s most vexing problems. Building on beneficial ...
... distribution models for revealing the response of animals ... the endangered marsupial, the Northern Bettong. The research, ... weather events, rather than the gradual changes of ... Bettong,s movements, range boundaries and likely contact with ...
... tropical parasitic disease that can lead to life-threatening heart ... than previously thought, according to research from The University ... for four years now, and this year the number ... professor of integrative biology and philosophy at The University ...
Cached Biology News:Virtual institutes to support the scientific collaborations of the future 2Virtual institutes to support the scientific collaborations of the future 3Australia's endangered bettong reveals how weather effects species distribution 2Chagas disease may be a threat in South Texas, says researcher 2
... The thermostable dUTPase(pyrococcus fruriosus) maximizes the ... DNA polymerases). It removes contaminating ... dNTP solutions. The presence of ... reaction can prevent dUTP misincorporation by ...
... the D-2000, but comes with a shutter (controlled ... The D-2000 Deuterium Light Source produces a ... deep-UV versions of the light source are available, ... powerful and stable lamp provides peak-to-peak stability of ...
... product for cell-based kinetic assays and research ... of expensive HTS equipment, which lead to ... development stage. The NOVOstar offers the right ... as any other assay suitable for the ...
... The kit measures mitochondria intactness ... mitochondrial membrane potential. Features and Benefits: ... method for staining isolated mitochondria and ... Contains all the reagents required for ...
Biology Products: